{"id":"W2797132528","doi":"10.1016/j.jaad.2018.04.012","title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":155,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Dermira","keywords":"Certolizumab pegol; Medicine; Placebo; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Clinical trial; Dermatology; Adalimumab; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0002961891,0.0004380283,0.002995938,0.0001739177,0.0003217375,0.00001130829,0.0006089545,0.0002637248,0.00002702699],"category_scores_gemma":[0.0003236594,0.0002134528,0.0009432425,0.0001878152,0.0031063,0.0001339349,0.00009249966,0.000281157,0.000008396218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001340879,"about_ca_system_score_gemma":0.000180443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002384774,"about_ca_topic_score_gemma":0.00004390772,"domain_scores_codex":[0.9961774,0.001153133,0.001761344,0.0003178898,0.0001178379,0.0004723716],"domain_scores_gemma":[0.9907397,0.004747163,0.003920281,0.0003273987,0.0002199056,0.00004552588],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9460765,0.00120176,0.0001890517,0.00003399393,0.01658207,0.00001697736,0.005061728,0.000006059258,0.009668657,0.0002031837,0.004198503,0.01676152],"study_design_scores_gemma":[0.8536887,0.002457784,0.0001497374,0.0001246829,0.005819882,0.001713341,0.002151785,0.00007629856,0.1164086,0.000491214,0.01670114,0.0002169044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9172409,0.05924299,0.0002137312,0.01921228,0.001472735,0.002242185,0.0003102044,0.00001517998,0.00004977759],"genre_scores_gemma":[0.9746199,0.02418355,0.0003430436,0.0001679408,0.0003517435,0.0001756249,0.000008940948,0.00002683701,0.0001224498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1067399,"threshold_uncertainty_score":0.9996067,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04701122508122613,"score_gpt":0.3529104809531127,"score_spread":0.3058992558718866,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}